TCG Advisory Services LLC Raises Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

TCG Advisory Services LLC boosted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 99.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,258 shares of the biopharmaceutical company’s stock after acquiring an additional 5,604 shares during the quarter. TCG Advisory Services LLC’s holdings in Bristol-Myers Squibb were worth $578,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of BMY. Lindbrook Capital LLC increased its stake in Bristol-Myers Squibb by 2.3% in the 3rd quarter. Lindbrook Capital LLC now owns 8,060 shares of the biopharmaceutical company’s stock worth $468,000 after buying an additional 182 shares during the period. Addison Advisors LLC increased its position in shares of Bristol-Myers Squibb by 6.6% during the third quarter. Addison Advisors LLC now owns 3,120 shares of the biopharmaceutical company’s stock worth $181,000 after acquiring an additional 192 shares during the period. Symphony Financial Ltd. Co. raised its stake in shares of Bristol-Myers Squibb by 4.1% during the third quarter. Symphony Financial Ltd. Co. now owns 4,980 shares of the biopharmaceutical company’s stock valued at $288,000 after acquiring an additional 194 shares in the last quarter. Blue Bell Private Wealth Management LLC boosted its holdings in shares of Bristol-Myers Squibb by 61.5% in the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 200 shares during the period. Finally, AMG National Trust Bank grew its stake in Bristol-Myers Squibb by 1.0% in the third quarter. AMG National Trust Bank now owns 19,685 shares of the biopharmaceutical company’s stock worth $1,143,000 after purchasing an additional 201 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Up 0.7 %

NYSE BMY traded up $0.29 during trading on Friday, hitting $43.99. The company’s stock had a trading volume of 12,104,489 shares, compared to its average volume of 14,314,010. Bristol-Myers Squibb has a fifty-two week low of $43.33 and a fifty-two week high of $69.10. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11 and a quick ratio of 0.99. The company has a market cap of $89.17 billion, a PE ratio of -14.19, a P/E/G ratio of 14.82 and a beta of 0.45. The business’s 50 day simple moving average is $50.37 and its 200-day simple moving average is $50.65.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping the consensus estimate of ($4.53) by $0.13. The company had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. Bristol-Myers Squibb’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.05 EPS. On average, equities analysts anticipate that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a yield of 5.46%. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on BMY shares. BMO Capital Markets decreased their target price on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research report on Friday, April 26th. Wells Fargo & Company lifted their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a report on Thursday, April 18th. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Finally, Redburn Atlantic cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $77.00 to $54.00 in a research report on Tuesday, February 6th. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $60.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.